Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lucid Diagnostics ( (LUCD) ) has provided an announcement.
Lucid Diagnostics reported financial results for the second quarter of 2025, with revenue of $1.2 million from 2,756 processed EsoGuard tests. The company ended the quarter with over $30 million in cash, extending its financial runway into 2026. Lucid is advancing towards securing Medicare coverage for EsoGuard, with a significant advisory committee meeting scheduled for September 4, 2025. The company has also initiated testing under a new insurance policy and partnered with Hoag to expand access to its testing programs. Additionally, Lucid joined the Russell 2000 and 3000 Indexes, enhancing its visibility among institutional investors.
The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
Spark’s Take on LUCD Stock
According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.
Lucid Diagnostics’ overall stock score is primarily impacted by its weak financial performance and unfavorable technical indicators. Despite the positive sentiment from recent corporate events, the company’s financial instability and negative valuation metrics weigh heavily on its attractiveness.
To see Spark’s full report on LUCD stock, click here.
More about Lucid Diagnostics
Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., operates in the medical diagnostics industry, focusing on cancer prevention. The company is known for its EsoGuard esophageal DNA test, which is used for nonendoscopic esophageal precancer testing. Lucid Diagnostics targets the Medicare population and works to expand its market presence through partnerships and insurance coverage.
Average Trading Volume: 1,181,769
Technical Sentiment Signal: Sell
Current Market Cap: $107.9M
For detailed information about LUCD stock, go to TipRanks’ Stock Analysis page.